INS and Alzheimer disease: Neuropathological AD changes have been associated with impaired cerebral insulin signaling (Takeda et al., 2010; Martinez-Valbuena et al., 2019), and decreased insulin signaling in the brain can inhibit phosphatidylinositol 3-kinase/Akt and activate GSK-3β (Ma et al., 2015).